Abstract
Three osteoinductive bone growth factors have proceeded sufficiently through preclinical studies to generate data from human trials. These osteoinductive factors include recombinant human bone morphogenetic protein-2, recombinant human bone morphogenetic protein-7/osteogenic protein-1, and a bovine extract from a mixture of bone morphogenetic proteins. Each program has its unique challenges with preclinical efficacy, safety, carrier, dose–concentration, and clinical trial design. This article compares and contrasts the programs as they pertain to the use of bone morphogenetic proteins for spine fusion.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
